Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 13 full-time employees. The company went IPO on 2012-05-25. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. The firm is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. The firm is utilizing its metabolism-based technology and is developing TYME-19 as a potential therapeutic for coronavirus, the virus that causes Covid-19.